Persistence of Hepatitis B Vaccine Immunity in Hemodialysis Patients
: Although the efficacy of hepatitis B vaccines in patients undergoing chronic hemodialysis (HD) treatment has been documented, the persistence of immunity in this population remains largely unknown. In this study we evaluated the persistence of hepatitis B vaccine immunity in HD patients. We follo...
Gespeichert in:
| Veröffentlicht in: | Therapeutic apheresis and dialysis 2008-04, Vol.12 (2), p.143-146 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 146 |
|---|---|
| container_issue | 2 |
| container_start_page | 143 |
| container_title | Therapeutic apheresis and dialysis |
| container_volume | 12 |
| creator | Ramezani, Amitis Velayati, Ali Akbar Eslamifar, Ali Banifazl, Mohammad Ahmadi, Farrokhlagha Maziar, Sima Razeghi, Effat Kalantar, Ebrahim Amirkhani, Aref Aghakhani, Arezoo |
| description | : Although the efficacy of hepatitis B vaccines in patients undergoing chronic hemodialysis (HD) treatment has been documented, the persistence of immunity in this population remains largely unknown. In this study we evaluated the persistence of hepatitis B vaccine immunity in HD patients. We followed 37 hepatitis B vaccinated HD patients (following a four‐dose vaccination schedule of 40 μg injections intramuscularly in the deltoid muscle at 0, 1, 2, and 6 months) for up to one year to evaluate the persistence of immunity (as indicated by serum levels of hepatitis B surface antibody (anti‐HBs) equal to or higher than 10 IU/L). One year after vaccination, 18.9% of patients had lost their anti‐HBs (transient responders), while 81.1% still had detectable antibodies in the serum (persistent responders). From 81.1% of persistent responders 11.5% and 88.5% were weak and high responders, respectively. There was no significant difference between persistent and transient responders regarding age, sex, or nutritional factors. We did not find any factors that related to maintaining protective levels of anti‐HBs in HD patients. It seems that an antibody titer above 100 IU/L following vaccination is necessary in order to maintain that level of antibody one year later. |
| doi_str_mv | 10.1111/j.1744-9987.2008.00560.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70476887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20716286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4590-da80b147264bff8c2f81b3360a7cb5a7746d9eaced530989ae2bc06362d1864d3</originalsourceid><addsrcrecordid>eNqNkctOwzAQRS0E4v0LKCt2CeNHbEdiA4UCEoIKFVhajuNILnmUOBXt3-PQqizBG48098zIxwhFGBIczsUswYKxOMukSAiATABSDslyBx1uG7vbWmQH6Mj7GQAhjNJ9dIAllQJzeohuJrbzzve2MTZqy-jeznXveuej6-hNG-MaGz3U9aJx_SpyTejXbeF0tQpQNAlR2_T-BO2VuvL2dHMfo9fx7XR0Hz8-3z2Mrh5jw9IM4kJLyDEThLO8LKUhpcQ5pRy0MHmqhWC8yKw2tkgpZDLTluQGOOWkwJKzgh6j8_Xcedd-LqzvVe28sVWlG9suvBLABJdS_BkkEF5PJA9BuQ6arvW-s6Wad67W3UphUINqNVODRTUYVYNq9aNaLQN6ttmxyGtb_IIbtyFwuQ58ucqu_j1YTa8moQh4vMaH31lucd19KC6oSNX70516YWM2msK1eqff8w-bRA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20716286</pqid></control><display><type>article</type><title>Persistence of Hepatitis B Vaccine Immunity in Hemodialysis Patients</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Ramezani, Amitis ; Velayati, Ali Akbar ; Eslamifar, Ali ; Banifazl, Mohammad ; Ahmadi, Farrokhlagha ; Maziar, Sima ; Razeghi, Effat ; Kalantar, Ebrahim ; Amirkhani, Aref ; Aghakhani, Arezoo</creator><creatorcontrib>Ramezani, Amitis ; Velayati, Ali Akbar ; Eslamifar, Ali ; Banifazl, Mohammad ; Ahmadi, Farrokhlagha ; Maziar, Sima ; Razeghi, Effat ; Kalantar, Ebrahim ; Amirkhani, Aref ; Aghakhani, Arezoo</creatorcontrib><description>: Although the efficacy of hepatitis B vaccines in patients undergoing chronic hemodialysis (HD) treatment has been documented, the persistence of immunity in this population remains largely unknown. In this study we evaluated the persistence of hepatitis B vaccine immunity in HD patients. We followed 37 hepatitis B vaccinated HD patients (following a four‐dose vaccination schedule of 40 μg injections intramuscularly in the deltoid muscle at 0, 1, 2, and 6 months) for up to one year to evaluate the persistence of immunity (as indicated by serum levels of hepatitis B surface antibody (anti‐HBs) equal to or higher than 10 IU/L). One year after vaccination, 18.9% of patients had lost their anti‐HBs (transient responders), while 81.1% still had detectable antibodies in the serum (persistent responders). From 81.1% of persistent responders 11.5% and 88.5% were weak and high responders, respectively. There was no significant difference between persistent and transient responders regarding age, sex, or nutritional factors. We did not find any factors that related to maintaining protective levels of anti‐HBs in HD patients. It seems that an antibody titer above 100 IU/L following vaccination is necessary in order to maintain that level of antibody one year later.</description><identifier>ISSN: 1744-9979</identifier><identifier>EISSN: 1744-9987</identifier><identifier>DOI: 10.1111/j.1744-9987.2008.00560.x</identifier><identifier>PMID: 18387163</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Hemodialysis patients ; Hepatitis B - immunology ; Hepatitis B Antibodies - blood ; Hepatitis B vaccine ; Hepatitis B Vaccines - immunology ; Humans ; Immunity, Active ; Male ; Middle Aged ; Persistent responders ; Prospective Studies ; Renal Dialysis ; Time Factors ; Transient responders ; Vaccination</subject><ispartof>Therapeutic apheresis and dialysis, 2008-04, Vol.12 (2), p.143-146</ispartof><rights>2008 The Authors</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4590-da80b147264bff8c2f81b3360a7cb5a7746d9eaced530989ae2bc06362d1864d3</citedby><cites>FETCH-LOGICAL-c4590-da80b147264bff8c2f81b3360a7cb5a7746d9eaced530989ae2bc06362d1864d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1744-9987.2008.00560.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1744-9987.2008.00560.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18387163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramezani, Amitis</creatorcontrib><creatorcontrib>Velayati, Ali Akbar</creatorcontrib><creatorcontrib>Eslamifar, Ali</creatorcontrib><creatorcontrib>Banifazl, Mohammad</creatorcontrib><creatorcontrib>Ahmadi, Farrokhlagha</creatorcontrib><creatorcontrib>Maziar, Sima</creatorcontrib><creatorcontrib>Razeghi, Effat</creatorcontrib><creatorcontrib>Kalantar, Ebrahim</creatorcontrib><creatorcontrib>Amirkhani, Aref</creatorcontrib><creatorcontrib>Aghakhani, Arezoo</creatorcontrib><title>Persistence of Hepatitis B Vaccine Immunity in Hemodialysis Patients</title><title>Therapeutic apheresis and dialysis</title><addtitle>Ther Apher Dial</addtitle><description>: Although the efficacy of hepatitis B vaccines in patients undergoing chronic hemodialysis (HD) treatment has been documented, the persistence of immunity in this population remains largely unknown. In this study we evaluated the persistence of hepatitis B vaccine immunity in HD patients. We followed 37 hepatitis B vaccinated HD patients (following a four‐dose vaccination schedule of 40 μg injections intramuscularly in the deltoid muscle at 0, 1, 2, and 6 months) for up to one year to evaluate the persistence of immunity (as indicated by serum levels of hepatitis B surface antibody (anti‐HBs) equal to or higher than 10 IU/L). One year after vaccination, 18.9% of patients had lost their anti‐HBs (transient responders), while 81.1% still had detectable antibodies in the serum (persistent responders). From 81.1% of persistent responders 11.5% and 88.5% were weak and high responders, respectively. There was no significant difference between persistent and transient responders regarding age, sex, or nutritional factors. We did not find any factors that related to maintaining protective levels of anti‐HBs in HD patients. It seems that an antibody titer above 100 IU/L following vaccination is necessary in order to maintain that level of antibody one year later.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hemodialysis patients</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B vaccine</subject><subject>Hepatitis B Vaccines - immunology</subject><subject>Humans</subject><subject>Immunity, Active</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Persistent responders</subject><subject>Prospective Studies</subject><subject>Renal Dialysis</subject><subject>Time Factors</subject><subject>Transient responders</subject><subject>Vaccination</subject><issn>1744-9979</issn><issn>1744-9987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctOwzAQRS0E4v0LKCt2CeNHbEdiA4UCEoIKFVhajuNILnmUOBXt3-PQqizBG48098zIxwhFGBIczsUswYKxOMukSAiATABSDslyBx1uG7vbWmQH6Mj7GQAhjNJ9dIAllQJzeohuJrbzzve2MTZqy-jeznXveuej6-hNG-MaGz3U9aJx_SpyTejXbeF0tQpQNAlR2_T-BO2VuvL2dHMfo9fx7XR0Hz8-3z2Mrh5jw9IM4kJLyDEThLO8LKUhpcQ5pRy0MHmqhWC8yKw2tkgpZDLTluQGOOWkwJKzgh6j8_Xcedd-LqzvVe28sVWlG9suvBLABJdS_BkkEF5PJA9BuQ6arvW-s6Wad67W3UphUINqNVODRTUYVYNq9aNaLQN6ttmxyGtb_IIbtyFwuQ58ucqu_j1YTa8moQh4vMaH31lucd19KC6oSNX70516YWM2msK1eqff8w-bRA</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>Ramezani, Amitis</creator><creator>Velayati, Ali Akbar</creator><creator>Eslamifar, Ali</creator><creator>Banifazl, Mohammad</creator><creator>Ahmadi, Farrokhlagha</creator><creator>Maziar, Sima</creator><creator>Razeghi, Effat</creator><creator>Kalantar, Ebrahim</creator><creator>Amirkhani, Aref</creator><creator>Aghakhani, Arezoo</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200804</creationdate><title>Persistence of Hepatitis B Vaccine Immunity in Hemodialysis Patients</title><author>Ramezani, Amitis ; Velayati, Ali Akbar ; Eslamifar, Ali ; Banifazl, Mohammad ; Ahmadi, Farrokhlagha ; Maziar, Sima ; Razeghi, Effat ; Kalantar, Ebrahim ; Amirkhani, Aref ; Aghakhani, Arezoo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4590-da80b147264bff8c2f81b3360a7cb5a7746d9eaced530989ae2bc06362d1864d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hemodialysis patients</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B vaccine</topic><topic>Hepatitis B Vaccines - immunology</topic><topic>Humans</topic><topic>Immunity, Active</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Persistent responders</topic><topic>Prospective Studies</topic><topic>Renal Dialysis</topic><topic>Time Factors</topic><topic>Transient responders</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramezani, Amitis</creatorcontrib><creatorcontrib>Velayati, Ali Akbar</creatorcontrib><creatorcontrib>Eslamifar, Ali</creatorcontrib><creatorcontrib>Banifazl, Mohammad</creatorcontrib><creatorcontrib>Ahmadi, Farrokhlagha</creatorcontrib><creatorcontrib>Maziar, Sima</creatorcontrib><creatorcontrib>Razeghi, Effat</creatorcontrib><creatorcontrib>Kalantar, Ebrahim</creatorcontrib><creatorcontrib>Amirkhani, Aref</creatorcontrib><creatorcontrib>Aghakhani, Arezoo</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic apheresis and dialysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramezani, Amitis</au><au>Velayati, Ali Akbar</au><au>Eslamifar, Ali</au><au>Banifazl, Mohammad</au><au>Ahmadi, Farrokhlagha</au><au>Maziar, Sima</au><au>Razeghi, Effat</au><au>Kalantar, Ebrahim</au><au>Amirkhani, Aref</au><au>Aghakhani, Arezoo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Persistence of Hepatitis B Vaccine Immunity in Hemodialysis Patients</atitle><jtitle>Therapeutic apheresis and dialysis</jtitle><addtitle>Ther Apher Dial</addtitle><date>2008-04</date><risdate>2008</risdate><volume>12</volume><issue>2</issue><spage>143</spage><epage>146</epage><pages>143-146</pages><issn>1744-9979</issn><eissn>1744-9987</eissn><abstract>: Although the efficacy of hepatitis B vaccines in patients undergoing chronic hemodialysis (HD) treatment has been documented, the persistence of immunity in this population remains largely unknown. In this study we evaluated the persistence of hepatitis B vaccine immunity in HD patients. We followed 37 hepatitis B vaccinated HD patients (following a four‐dose vaccination schedule of 40 μg injections intramuscularly in the deltoid muscle at 0, 1, 2, and 6 months) for up to one year to evaluate the persistence of immunity (as indicated by serum levels of hepatitis B surface antibody (anti‐HBs) equal to or higher than 10 IU/L). One year after vaccination, 18.9% of patients had lost their anti‐HBs (transient responders), while 81.1% still had detectable antibodies in the serum (persistent responders). From 81.1% of persistent responders 11.5% and 88.5% were weak and high responders, respectively. There was no significant difference between persistent and transient responders regarding age, sex, or nutritional factors. We did not find any factors that related to maintaining protective levels of anti‐HBs in HD patients. It seems that an antibody titer above 100 IU/L following vaccination is necessary in order to maintain that level of antibody one year later.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>18387163</pmid><doi>10.1111/j.1744-9987.2008.00560.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1744-9979 |
| ispartof | Therapeutic apheresis and dialysis, 2008-04, Vol.12 (2), p.143-146 |
| issn | 1744-9979 1744-9987 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70476887 |
| source | MEDLINE; Wiley Journals |
| subjects | Adult Aged Aged, 80 and over Female Follow-Up Studies Hemodialysis patients Hepatitis B - immunology Hepatitis B Antibodies - blood Hepatitis B vaccine Hepatitis B Vaccines - immunology Humans Immunity, Active Male Middle Aged Persistent responders Prospective Studies Renal Dialysis Time Factors Transient responders Vaccination |
| title | Persistence of Hepatitis B Vaccine Immunity in Hemodialysis Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A18%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Persistence%20of%20Hepatitis%20B%20Vaccine%20Immunity%20in%20Hemodialysis%20Patients&rft.jtitle=Therapeutic%20apheresis%20and%20dialysis&rft.au=Ramezani,%20Amitis&rft.date=2008-04&rft.volume=12&rft.issue=2&rft.spage=143&rft.epage=146&rft.pages=143-146&rft.issn=1744-9979&rft.eissn=1744-9987&rft_id=info:doi/10.1111/j.1744-9987.2008.00560.x&rft_dat=%3Cproquest_cross%3E20716286%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20716286&rft_id=info:pmid/18387163&rfr_iscdi=true |